Surface modifications of influenza proteins upon virus inactivation by β-propiolactone

Proteomics

Volumn 13, Issue 23-24, 2013, Pages 3537-3547

  She, Yi Min ^a   Cheng, Keding ^b   Farnsworth, Aaron ^a   Li, Xuguang ^a   Cyr, Terry D ^a  

^a HEALTH CANADA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Propiolactone; Biomedicine; Influenza vaccine; MS; PTM; Virus inactivation

Indexed keywords

CYSTEINE; GLYCOPEPTIDE; INFLUENZA VACCINE; NIBRG 121XP; NYMC X 181A; PROPIOLACTONE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; ENZYME ACTIVITY; GLYCOSYLATION; INFLUENZA VIRUS; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MOLECULAR SIZE; NONHUMAN; PALMITOYLATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEOMICS; VIRUS INACTIVATION;

BIOMEDICINE; INFLUENZA VACCINE; MS; PTM; VIRUS INACTIVATION; Β-PROPIOLACTONE;

AMINO ACID SEQUENCE; ANTIGENS, VIRAL; CYSTEINE; HEMAGGLUTININS; INFLUENZA VACCINES; NEURAMINIDASE; POLYSACCHARIDES; PROPIOLACTONE; RNA-BINDING PROTEINS; TANDEM MASS SPECTROMETRY; VIRAL CORE PROTEINS; VIRAL PROTEINS; VIRUS INACTIVATION;

EID: 84890252463     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300096     Document Type: Article

References (35)

1. Taubenberger, J. K., Morens, D. M., The pathology of influenza virus infections. Annu. Rev. Pathol. 2008, 3, 499-522.
2. Wood, J. M., Robertson, J. S., From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2004, 2, 842-847.
3. Chen, J. R., Ma, C., Wong, C. H., Vaccine design of hemagglutinin glycoprotein against influenza. Trends Biotechnol. 2011, 29, 426-434.
4. Robertson, J. S., Nicolson, C., Harvey, R., Johnson, R. et al., The development of vaccine viruses against pandemic A (H1N1) influenza. Vaccine 2011, 29, 1836-1843.
5. Nicolson, C., Harvey, R., Johnson, R., Guilfoyle, K. et al., An additional oligosaccharide moiety in the HA of a pandemic influenza H1N1 candidate vaccine virus confers increased antigen yield in eggs. Vaccine 2012, 30, 745-751.
6. Nicholson, K. G., Wood, J. M., Zambon, M., Influenza. Lancet 2003, 362, 1733-1745.
7. Uittenbogaard, J. P., Zomer, B., Hoogerhout, P., Metz, B., Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses. J. Biol. Chem. 2011, 286, 36198-36214.
8. Jonges, M., Liu, W. M., van der Vries, E., Jacobi, R. et al., Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. J. Clin. Microbiol. 2010, 48, 928-940.
9. Furuya, Y., Regner, M., Lobigs, M., Koskinen, A. et al., Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. J. Gen. Virol. 2010, 91(Pt 6), 1450-1460.
10. Goldstein, M. A., Tauraso, N. M., Effect of formalin, beta-propiolactone, merthiolate, and ultraviolet light upon influenza virus infectivity chicken cell agglutination, hemagglutination, and antigenicity. Appl. Microbiol. 1970, 19, 290-294.
11. Farnsworth, A., Cyr, T. D., Li, C., Wang, J. et al., Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 2011, 29, 1529-1533.
12. Budowsky, E. I., Smirnov, Y. A., Shenderovich, S. F., Principles of selective inactivation of viral genome. VIII. The influence of β-propiolactone on immunogenic and protective activities of influenza virus. Vaccine 1993, 11, 343-348.
13. Desbat, B., Lancelot, E., Krell, T., Nicolaï, M. C. et al., Effect of the β-propiolactone treatment on the adsorption and fusion of influenza A/Brisbane/59/2007 and A/New Caledonia/20/1999 virus H1N1 on a dimyristoylphosphatidylcholine/ganglioside GM3 mixed phospholipids monolayer at the air-water interface. Langmuir. 2011, 27, 13675-13683.
14. Drisdel, R. C., Green, W. N., Labeling and quantifying sites of protein palmitoylation. Biotechniques. 2004, 36, 276-285.
15. Drisdel, R. C., Alexander, J. K., Sayeed, A., Green, W. N., Assays of protein palmitoylation. Methods 2006, 40, 127-134.
16. Creskey, M. C., Smith, D. G., Cyr, T. D., Strain identification of commercial influenza vaccines by mass spectrometry. Anal. Biochem. 2010, 406, 193-203.
17. Kordyukova, L. V., Serebryakova, M. V., Baratova, L. A., Veit, M. S., acylation of the hemagglutinin of influenza viruses: mass spectrometry reveals site-specific attachment of stearic acid to a transmembrane cysteine. J. Virol. 2008, 82, 9288-9292.
18. Kordyukova, L. V., Serebryakova, M. V., Baratova, L. A., Veit, M., Site-specific attachment of palmitate or stearate to cytoplasmic versus transmembrane cysteines is a common feature of viral spike proteins. Virology 2010, 398, 49-56.
19. Air, G. M., Nucleotide sequence coding for the "signal peptide" and N terminus of the hemagglutinin from an Asian (H2N2) strain of influenza virus. Virology 1979, 97, 468-472.
20. Krokhin, O. V., Antonovici, M., Ens, W., Wilkins, J. A. et al., Deamidation of -Asn-Gly- sequences during sample preparation for proteomics: consequences for MALDI and HPLC-MALDI analysis. Anal. Chem. 2006, 78, 6645-6650.
21. Polevoda, B., Sherman, F., N-terminal acetylation of eukaryotic proteins. J. Biol. Chem. 2000, 275, 36479-36482.
22. Wang, C. C., Chen, J. R., Tseng, Y. C., Hsu, C. H. et al., Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl. Acad. Sci. U S A. 2009, 106, 18137-18142.
23. Allison, W. S., Formation and reactions of sulfenic acids in proteins. Accts. Chem. Res. 1976, 9, 293-299.
24. Rehder, D. S., Borges, C. R., Cysteine sulfenic acid as an intermediate in disulfide bond formation and nonenzymatic protein folding. Biochemistry. 2010, 49, 7748-7755.
25. Poole, L. B., Karplus, P. A., Claiborne, A., Protein sulfenic acids in redox signaling. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 325-347.
26. Xu, R., Ekiert, D. C., Krause, J. C., Hai, R. et al., Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010, 328, 357-360.
27. Xu, X., Zhu, X., Dwek, R. A. et al., Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J. Virol. 2008, 82, 10493-10501.
28. Waterfield, M., Scrace, G., Skehel, J., Disulphide bonds of haemagglutinin of Asian influenza virus. Nature 1981, 289, 422-424.
29. Ward, C. W., Colman, P. M., Laver, W. G., The disulphide bonds of an Asian influenza virus neuraminidase. FEBS Lett. 1983, 153, 29-33.
30. Varghese, J. N., Laver, W. G., Colman, P. M., Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983, 303, 35-40.
31. Metz, B., Kersten, G. F., Hoogerhout, P., Brugghe, H. F. et al., Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J. Biol. Chem. 2004, 279, 6235-6243.
32. Metz, B., Kersten, G. F., Baart, G. J., de Jong, A. et al., Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug. Chem. 2006, 17, 815-822.
33. Taubman, M. A., Atassi, M. Z., Reaction of beta-propiolactone with amino acids and its specificity for methionine. Biochem. J. 1968, 106, 829-834.
34. Gamblin, S. J., Skehel, J. J., Influenza hemagglutinin and neuraminidase membrane glycoproteins. J. Biol. Chem. 2010, 285, 28403-28409.
35. Yen, H. L., Hoffmann, E., Taylor, G., Scholtissek, C. et al., Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 2006, 80, 8787-8795.